Full Press Release Details
EMERYVILLE, Calif.,Aug. 21, 2024/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that the company's executives will participate in the following investor events:
Investor Conference Details:
• Morgan Stanley Global Healthcare Conference inNew York, NYonSeptember 4, 2024Format: Fireside Chat with Mike Ulz at11:30 am EDTand host investor meetings
• Wells Fargo Healthcare Conference inBoston, MAonSeptember 5, 2024Format: Fireside Chat withDerek Archilaat2:15 pm EDTand host investor meetings
• Cantor Global Healthcare Conference inNew York, NYonSeptember 17, 2024Format: Fireside Chat withEric Schmidtat10:20 am EDTand host investor meetings
Investors interested in scheduling a meeting with management during one of the investor conferences listed above should contact their Morgan Stanley, Wells Fargo, or Cantor sales representative.
About Kyverna TherapeuticsKyverna Therapeutics, Inc. (Nasdaq:KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
Our lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials inthe United StatesandGermanyfor patients with lupus nephritis.
Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna's expected participation in upcoming investor conferences; Kyverna's ongoing clinical trials; Kyverna's pipeline and the potential for Kyverna's CAR T-cell therapies to be well suited for use in B cell-driven autoimmune diseases. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please visithttps://kyvernatx.com.Investor Contact:George ThampyKyverna Therapeutics[email protected]
Kyverna Media Contact:Consort Partners for Kyverna[email protected]